Biotechnology incubator Accelerator has snagged a commitment of about $5 million from a new investor to fund additional startups.
Accelerator, a Seattle-based incubator for biotechnology companies, snagged a commitment of about $5 million from a new investor to fund additional startups.
The commitment will bring to $27 million for the Accelerator’s third round of investment, dubbed Accelerator III. The investor, PPD, is a large contract clinical research and development company based in Wilmington, N.C.
Accelerator Chief Executive Carl Weissman said PPD’s expertise “should make a huge impact” in its farm team of young biotechs.
Accelerator’s funding will allow it to invest in three or four more startups over the next few years.
Most Read Business Stories
- Seattle among top markets as U.S. home prices increase by double-digit percentages for the first time in years
- Another top Amazon executive to leave company
- Boeing 757 bound for Seattle makes emergency landing
- REI picks new satellite office ‘surrounded by trail networks’
- Alaska Airlines ordered to pay $3.2M to family of woman who died after escalator fall
At a time when few companies are willing to part with cash, PPD’s involvement underscores its long-term thinking as an investor, said David Schubert, the Accelerator’s chief business officer.
“They never even blinked when the economy or the markets went into turmoil,” Schubert said.
In August Accelerator netted an initial $22.5 million for the third investment round.
Other investors include Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, WRF Capital and Alexandria Real Estate Equities.
The Accelerator has invested in nine early stage companies, three of which have left the incubator and collectively raised more than $114 million.
Ángel González: 206-515-5644 or firstname.lastname@example.org